(0.39%) 5 207.83 points
(0.56%) 39 277 points
(0.31%) 16 353 points
(0.28%) $79.21
(4.34%) $2.28
(0.72%) $2 339.00
(2.74%) $28.36
(0.72%) $991.65
(-0.26%) $0.928
(-0.28%) $10.86
(-0.19%) $0.799
(0.84%) $92.51
Quarter results today
(bmo 2024-05-09)
Expected move: +/- 9.89%
Live Chart Being Loaded With Signals
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States...
Stats | |
---|---|
Šios dienos apimtis | 109 949 |
Vidutinė apimtis | 678 713 |
Rinkos kapitalizacija | 31.48M |
EPS | $0 ( 2024-03-28 ) |
Kita pelno data | ( $-0.0600 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.890 |
ATR14 | $0.00300 (0.96%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-12 | Fair John A | Buy | 290 000 | Employee Stock Option (right to buy) |
2024-03-12 | Johnson Sabrina Martucci | Buy | 750 000 | Employee Stock Option (right to buy) |
2024-03-12 | Haring-layton Mardee | Buy | 290 000 | Employee Stock Option (right to buy) |
2024-01-26 | Haring-layton Mardee | Sell | 3 500 | Employee Stock Option (right to buy) |
2024-01-26 | Haring-layton Mardee | Sell | 30 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
78.57 |
Last 91 transactions |
Buy: 10 072 923 | Sell: 492 500 |
Tūris Koreliacija
Dare Bioscience Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
PRPO | 0.884 |
BCDA | 0.881 |
UCL | 0.875 |
SNDL | 0.872 |
AQB | 0.872 |
JOAN | 0.87 |
POTX | 0.87 |
AQMS | 0.87 |
STAF | 0.87 |
BLNK | 0.868 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
LEDS | -0.902 |
MPRA | -0.871 |
MTEK | -0.865 |
OBNK | -0.861 |
PUCKU | -0.841 |
MTEM | -0.838 |
BWMX | -0.836 |
NCAC | -0.834 |
MTCR | -0.832 |
CCRC | -0.83 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Dare Bioscience Inc Koreliacija - Valiuta/Žaliavos
Dare Bioscience Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $2.81M |
Bruto pelnas: | $2.77M (98.63 %) |
EPS: | $-0.350 |
FY | 2023 |
Pajamos: | $2.81M |
Bruto pelnas: | $2.77M (98.63 %) |
EPS: | $-0.350 |
FY | 2022 |
Pajamos: | $10.00M |
Bruto pelnas: | $9.95M (99.52 %) |
EPS: | $4.81 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-0.630 |
Financial Reports:
No articles found.
Dare Bioscience Inc
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.